Published in Hepatology on June 01, 2005
Weight Management in Nonalcoholic Steatohepatitis | NCT00266019
Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis | NCT01210989
Anti-Fibrotic Effects of Losartan In Nash Evaluation Study (FELINE) | NCT01051219
Predictable MR Index for Nonalcoholic Steatohepatitis (NASH) | NCT03375008
Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD | NCT03725631
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes | NCT02964715
Development of a Breath Test for Monitoring Patients With Liver Disease | NCT00244569
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis (EASYBEinNASH) | NCT03198572
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 10.74
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet (2014) 6.84
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut (2009) 4.01
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology (2014) 4.01
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology (2010) 3.73
Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci (2010) 3.72
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology (2010) 3.52
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol (2006) 3.46
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab (2008) 3.45
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther (2012) 3.25
Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology (2008) 3.04
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology (2012) 2.93
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2014) 2.90
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res (2009) 2.75
Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A (2014) 2.68
Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology (2013) 2.64
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest (2012) 2.62
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol (2011) 2.56
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology (2015) 2.49
Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One (2011) 2.48
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology (2010) 2.45
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology (2011) 2.42
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology (2013) 2.42
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A (2011) 2.39
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol (2010) 2.36
PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology (2010) 2.35
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology (2008) 2.33
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature (2014) 2.30
Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat Commun (2013) 2.29
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.25
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. Hepatology (2014) 2.23
NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology (2014) 2.22
Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol (2008) 2.22
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer (2009) 2.19
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol (2011) 2.15
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (2012) 2.10
Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol (2010) 2.09
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2012) 2.08
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol (2010) 2.06
The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol (2010) 2.05
Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia (2009) 2.03
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology (2013) 2.03
Advances in pediatric nonalcoholic fatty liver disease. Hepatology (2009) 2.03
Protective effects of dietary avocado oil on impaired electron transport chain function and exacerbated oxidative stress in liver mitochondria from diabetic rats. J Bioenerg Biomembr (2015) 2.01
Diets containing sea cucumber (Isostichopus badionotus) meals are hypocholesterolemic in young rats. PLoS One (2013) 2.01
Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology (2014) 2.00
A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology (2014) 2.00
Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon (2011) 1.99
An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol (2011) 1.98
Ethnicity and nonalcoholic fatty liver disease. Hepatology (2012) 1.98
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab (2012) 1.97
Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol (2008) 1.90
Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology (2012) 1.89
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol (2012) 1.87
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82
Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med (2008) 1.82
Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr (2012) 1.82
Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology (2011) 1.80
Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology (2013) 1.80
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J (2012) 1.79
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology (2013) 1.78
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology (2013) 1.77
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
Hepatic parenchymal preservation surgery: decreasing morbidity and mortality rates in 4,152 resections for malignancy. J Am Coll Surg (2014) 1.76
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol (2016) 1.76
Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol (2010) 1.75
Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2008) 1.74
Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf) (2014) 1.74
Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol (2008) 1.73
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver (2012) 1.70
Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One (2015) 1.68
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature (2008) 10.84
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med (2000) 8.32
Prevalence of fatty liver in children and adolescents. Pediatrics (2006) 7.00
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Alcoholic liver disease. Hepatology (2010) 5.04
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology (2005) 4.21
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology (2010) 3.73
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol (2010) 3.36
Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol (2012) 3.32
IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest (2007) 3.31
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
Estimation of impact of American College of Radiology recommendations on CT colonography reporting for resection of high-risk adenoma findings. Am J Gastroenterol (2009) 3.18
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum (2007) 3.12
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol (2012) 2.89
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology (2009) 2.88
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Sepsis-induced cholestasis. Hepatology (2007) 2.80
Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr (2003) 2.77
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology (2003) 2.59
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol (2004) 2.47
Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol (2008) 2.45
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology (2010) 2.45
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis (2007) 2.42
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res (2006) 2.35
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology (2008) 2.33
Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology (2010) 2.30
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg (2004) 2.29
Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol (2007) 2.28
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Afternoon colonoscopies have higher failure rates than morning colonoscopies. Am J Gastroenterol (2006) 2.21
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol (2009) 2.16
Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology (2009) 2.16
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol (2011) 2.15
Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology (2002) 2.13
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg (2007) 2.10
Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology (2008) 2.10
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (2012) 2.10
Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol (2011) 2.09
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology (2009) 2.07
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int (2014) 2.05
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology (2006) 2.04